Pancreatic tumor organoids pave the way for single-cell diagnostics
October 2021
Berlin Institute of Health (BIH)/Charité-Universitätsmedizin Berlin, Berlin, Germany(1)
Medical University of Vienna, Vienna, Austria(2)
Medical University of Vienna, Vienna, Austria(2)
Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of cancer mortality by 2030. Bulk transcriptomic analyses have distinguished ‘classical’ from ‘basal-like’ tumors with more aggressive clinical behaviour. Here, the researchers derive PDAC organoids from 18 primary tumors and two matched liver metastases, and show that ‘classical’ and ‘basal-like’ cells coexist in individual organoids. By single-cell transcriptome analysis of PDAC organoids and primary PDAC, they identify distinct tumor cell states shared across patients. In an imaging-based drug screen, expression of ‘classical’ subtype genes correlates with better drug response. These results thus uncover a functional hierarchy of PDAC cell states linked to transcriptional tumor subtypes and support the use of PDAC organoids as a clinically relevant model for in vitro studies of tumor heterogeneity.
Single-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental hierarchy
Roland Eils(1), Christian Conrad(1), Oliver Strobel(2)
Added on: 05-12-2022
[1] https://www.nature.com/articles/s41467-021-26059-4[2] https://www.bionity.com/en/news/1173535/the-subtle-difference-pancreatic-tumor-organoids-pave-the-way-for-single-cell-diagnostics.html
